Share Price | Zura Bio Ltd. Stock Analysis & Recommendation

Q: Is Zura Bio Ltd. technically bullish or bearish?

As of 9 September 2025, the technical trend for Zura Bio Ltd. has changed from sideways to mildly bullish. The weekly MACD is bullish, while the monthly MACD is mildly bullish. The daily moving averages also indicate a bullish stance. However, the Bollinger Bands show a mildly bearish trend on the monthly timeframe, and the KST is bearish on the monthly while bullish on the weekly. The Dow Theory supports a mildly bullish outlook on both weekly and monthly timeframes. In terms of returns, Zura Bio Ltd. has outperformed the S&P 500 over the past week and month, with returns of 1.49% and 17.82% respectively, but has significantly underperformed over the year and three years, with returns of -50.36% and -79.56%. Overall, the current technical stance is mildly bullish, driven by the positive signals from MACD and moving averages, despite some mixed indicators.

Q: What does Zura Bio Ltd. do?

Overview: Zura Bio Ltd. operates in the Pharmaceuticals & Biotechnology industry and is categorized as a micro-cap company.Financial Snapshot: Net Profit: -17 Million (Quarterly Results - Mar 2025) Market cap: USD 70.54 Million (Micro Cap)Key Metrics: P/E: NA (Loss Making) Industry P/E: NA Dividend Yield: 0.00% Debt Equity: -1.23 Return on Equity: -41.58% Price to Book: 0.51Contact Details: Details: No Company Details Available Registrar Address: Not available.

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

609.48 k

Shareholding (Mar 2026)

FII

2.47%

Held by 29 FIIs

DII

87.40%

Held by 11 DIIs

Promoter

10.13%

Is Zura Bio Ltd. technically bullish or bearish?

20-Sep-2025

As of September 9, 2025, Zura Bio Ltd. shows a mildly bullish trend supported by positive MACD and moving averages, despite mixed signals from Bollinger Bands and KST, while outperforming the S&P 500 recently but underperforming over the past year and three years.

View full answer

How big is Zura Bio Ltd.?

22-Jun-2025

As of Jun 18, Zura Bio Ltd. has a market capitalization of 70.54 million, with net sales of 0.00 million and a net profit of -62.10 million over the latest four quarters. As of Dec 24, shareholder's funds are at 146.81 million and total assets at 179.53 million.

View full answer

What does Zura Bio Ltd. do?

22-Jun-2025

Zura Bio Ltd. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, currently reporting a net profit loss of $17 million and a market cap of $70.54 million. Key metrics include a P/E ratio of NA, a dividend yield of 0.00%, and a return on equity of -41.58%.

View full answer

Compare Zura Bio Ltd. with Similar Stocks

23andMe Holding Co.Humacyte, Inc.uniQure NV

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 563 Million (Micro Cap)

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-1.08

Return on Equity

-67.61%

Price to Book

5.54

Revenue and Profits:

Net Sales:

(Quarterly Results - Mar 2026)

Net Profit:

-24 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-23.09%

6 Months

-2.76%

1 Year

274.34%

2 Years

23.68%

3 Years

-64.63%

4 Years

-57.44%

5 Years

0.0%

Zura Bio Ltd. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

EBIT Growth (5y)

-392.66%

EBIT to Interest (avg)

-43.97

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-1.23

Sales to Capital Employed (avg)

0.56

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

59.86%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

5.54

EV to EBIT

-6.02

EV to EBITDA

-6.03

EV to Capital Employed

-57.60

EV to Sales

PEG Ratio

Dividend Yield

ROCE (Latest)

Negative Capital Employed

ROE (Latest)

-67.61%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Mildly Bearish

Bullish

RSI

No Signal

Bollinger Bands

Bullish

Mildly Bullish

Moving Averages

Mildly Bullish (Daily)

KST

Mildly Bearish

Bullish

Dow Theory

No Trend

OBV

Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Mar 2026

Shareholding Compare (%holding)

Majority shareholders

Strategic Entities

Domestic Funds

Held in 20 Schemes (4.97%)

Foreign Institutions

Held by 29 Foreign Institutions (2.47%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Mar'26 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Mar 2026 is 0.00% vs 0.00% in Mar 2025",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Mar 2026 is -39.08% vs -125.97% in Mar 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Mar'26",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-25.50",
          "val2": "-19.20",
          "chgp": "-32.81%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-24.20",
          "val2": "-17.40",
          "chgp": "-39.08%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2025 is 0.00% vs 0.00% in Dec 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2025 is -31.11% vs 13.53% in Dec 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-75.20",
          "val2": "-55.20",
          "chgp": "-36.23%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "-5.20",
          "chgp": "100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-68.70",
          "val2": "-52.40",
          "chgp": "-31.11%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Mar'26 - YoY

Mar'26

Mar'25

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-25.50

-19.20

-32.81%

Interest

0.00

Exceptional Items

0.00

Consolidate Net Profit

-24.20

-17.40

-39.08%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Mar 2026 is 0.00% vs 0.00% in Mar 2025

Consolidated Net Profit

YoY Growth in quarter ended Mar 2026 is -39.08% vs -125.97% in Mar 2025

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'25

Dec'25

Dec'24

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-75.20

-55.20

-36.23%

Interest

0.00

Exceptional Items

0.00

-5.20

100.00%

Consolidate Net Profit

-68.70

-52.40

-31.11%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2025 is 0.00% vs 0.00% in Dec 2024

Consolidated Net Profit

YoY Growth in year ended Dec 2025 is -31.11% vs 13.53% in Dec 2024

All Annual Results

Company CV

About Zura Bio Ltd.

Zura Bio Ltd.

Pharmaceuticals & Biotechnology

No Details Available.

Company Coordinates

No Company Details Available